Ticker Scorecard - CLDX Basics Company: Celldex Therapeutics, Inc. IPO Date: March 26, 1990 Sector: Healthcare Industry: Biotech Market Cap: $1.54B Activated in VL: True Average Daily Range Avg Daily Range: $0.43 | 3.06% Avg Daily Range (30 D): $0.59 | 2.34% Avg Daily Range (90 D): $0.74 | 2.64% Institutional Daily Volume Avg Daily Volume: .27M Avg Daily Volume (30 D): .71M Avg Daily Volume (90 D): .87M Trade Size Avg Trade Size (Sh.): 40 Avg Trade Size (Sh.) (30 D): 56 Avg Trade Size (Sh.) (90 D): 68 Institutional Trades Total Inst.Trades: 4,208 Avg Inst. Trade: $2.07M Avg Inst. Trade (30 D): $3.54M Avg Inst. Trade (90 D): $2.85M Avg Inst. Trade Volume: .05M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.87M Avg Closing Trade (30 D): $5.27M Avg Closing Trade (90 D): $4.46M Avg Closing Volume: 71.22K     News Dec 19, 2024 @ 1:01 PM Celldex Initiates Phase 2 Study of Barzolvolimab i... Source: N/A Nov 4, 2024 @ 6:00 PM Urticaria Clinical Trial Pipeline Accelerates: 20+... Source: Delveinsight Oct 26, 2024 @ 9:43 PM Celldex Announces Barzolvolimab Met All Primary an... Source: N/A Oct 25, 2024 @ 12:01 PM Celldex Announces Upcoming Late Breaking Oral Pres... Source: N/A Jul 16, 2024 @ 7:01 PM Analyst Expectations For Celldex Therapeutics's Fu... Source: Benzinga Insights, Benzinga Staff Writer Financials   TTM Q3 2024 Q2 2024 Basic EPS $-2.58 $-.64 $-.54 Diluted EPS $-2.58 $-.64 $-.54 Revenue $ 9.98M $ 3.19M $ 2.5M Gross Profit $ $ $ Net Income / Loss $ -154.08M $ -42.12M $ -35.84M Operating Income / Loss $ -186.68M $ -52.13M $ -46.32M Cost of Revenue $ $ $ Net Cash Flow $ 15.27M $ -6.34M $ -72.34M PE Ratio     Splits Feb 11, 2019:   15:1 Mar 10, 2008:   12:1 Mar 07, 2008:   12:1